CHINA’S STROKE RATE IS HIGHEST
Neuralstem doses ischemic stroke patient with stem cells directly into the brain
By Shannon Ellis
Wednesday, February 5, 2014
SHANGHAI – Neuralstem Inc. has dosed its first patient with NSI-566 stem cells, commencing the Phase I/II trial in China for ischemic stroke.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.